Department of Radiation Oncology, Sheba Medical Center, Ramat Gan, Israel.
Department of Radiation Oncology, Haaglanden Medical Center, Leidschendam, The Netherlands.
Clin Oncol (R Coll Radiol). 2024 Nov;36(11):690-700. doi: 10.1016/j.clon.2024.08.012. Epub 2024 Aug 24.
The aim of the current study is to compare the dosimetry of 3 radiation therapy (RT) techniques used in the EORTC 22922/10925 trial for irradiating the internal mammary (IM) and medial supraclavicular nodes (MS) using a treatment planning system available nowadays for dose calculation.
We performed a retrospective dosimetry analysis of anonymised data; thus, ethics approval was not required. Ten cases of left-sided breast were randomly selected for RT planning to a total dose of 50 Gy in 25 fractions. The treatment planning was done according to the trial's protocol and under the supervision of the EORTC trial's coordinators. Doses to planning target volumes (PTV) and to organs at risk (OARs) are reported. Data is presented in descriptive statistics.
A total of 10 cases and 40 treatment plans (4 plans per case: standard-plan A, modified standard-plan B, individualised-plan C and breast-only-plan D). For all planning techniques, the mean dose to the PTV of the left breast (plan A-D) and the PTV-MS (plan A-C) exceeded 95% of the prescribed dose (>47.5 Gy). The individualised technique (plan C) had a lower coverage for PTV-IM, with a mean of 87% of the prescribed dose compared to ∼102% for plans A and B. The dose to OARs varied between techniques, with the mean heart dose being higher in the standard and modified standard techniques (18.3 and 16.6 Gy, respectively) compared to the individualised technique (9.5 Gy).
The 3 RT techniques used in the trial varied in target coverage and OARs dose. Our results may help to understand the observed larger absolute benefit of individualised IM-MS treatment planning in terms of breast cancer outcomes.
本研究旨在比较目前的三种放射治疗(RT)技术在 EORTC 22922/10925 试验中的剂量学,该试验使用现有的治疗计划系统对内部乳腺(IM)和内侧锁骨上淋巴结(MS)进行照射。
我们对匿名数据进行了回顾性剂量分析;因此,不需要伦理批准。随机选择 10 例左侧乳腺癌患者进行总剂量为 50Gy/25 次的 RT 计划。治疗计划按照试验方案进行,并在 EORTC 试验协调员的监督下进行。报告了计划靶区(PTV)和危及器官(OAR)的剂量。数据以描述性统计呈现。
共 10 例患者和 40 个治疗计划(每例 4 个计划:标准计划 A、改良标准计划 B、个体化计划 C 和仅乳房计划 D)。对于所有的计划技术,左乳 PTV(计划 A-D)和 PTV-MS(计划 A-C)的平均剂量均超过了处方剂量的 95%(>47.5Gy)。个体化技术(计划 C)对 PTV-IM 的覆盖度较低,平均为处方剂量的 87%,而计划 A 和 B 则为 102%左右。OAR 之间的剂量技术不同,标准和改良标准技术的平均心脏剂量分别为 18.3Gy 和 16.6Gy,而个体化技术为 9.5Gy。
试验中使用的三种 RT 技术在靶区覆盖度和 OAR 剂量方面存在差异。我们的结果可能有助于理解在乳腺癌结局方面观察到的个体化 IM-MS 治疗计划的更大绝对获益。